| Literature DB >> 36045428 |
Qinyuan Tan1, Hanxiang Le2, Chao Tang1, Ming Zhang1, Weijie Yang1, Yazhao Hong3, Xiaoqing Wang4.
Abstract
Injuries to the urethra can be caused by malformations, trauma, inflammation, or carcinoma, and reconstruction of the injured urethra is still a significant challenge in clinical urology. Implanting grafts for urethroplasty and end-to-end anastomosis are typical clinical interventions for urethral injury. However, complications and high recurrence rates remain unsatisfactory. To address this, urethral tissue engineering provides a promising modality for urethral repair. Additionally, developing tailor-made biomimetic natural and synthetic grafts is of great significance for urethral reconstruction. In this work, tailor-made biomimetic natural and synthetic grafts are divided into scaffold-free and scaffolded grafts according to their structures, and the influence of different graft structures on urethral reconstruction is discussed. In addition, future development and potential clinical application strategies of future urethral reconstruction grafts are predicted.Entities:
Keywords: Biomimetic structure; Natural graft; Precise urethral reconstruction; Synthetic graft; Tissue engineering
Mesh:
Year: 2022 PMID: 36045428 PMCID: PMC9429763 DOI: 10.1186/s12951-022-01599-z
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 9.429
Fig. 1Schematic illustration of tailor-made natural and synthetic grafts for precise urethral reconstruction
Overview of studies describing the use of scaffold-free grafts in urethral reconstruction
| Scaffold-free grafts | Biomaterials | Clinical/preclinical experiment | Animals for modeling | Average repair length | Follow-up/study period | In vivo/In vitro | Results | References |
|---|---|---|---|---|---|---|---|---|
| Flaps and patches | Dorsal penile flap | Clinical | NA | 5 cm | 3years | In vivo | Overall success rate is 88%; restore urethra function; provide cosmetic effects | [ |
| Oral mucosal grafts | Clinical | NA | 3–5 cm | At least 1year | In vivo | overall success rate is 85%; reduced operation time | [ | |
| BM | Preclinical | Rabbit | 1.5 cm | 3months | In vivo | induce angiogenesis; repair urethra tissue effectively | [ | |
| Skeletal muscle | Preclinical | Rabbit | 0.5 cm | 12 weeks | In vivo | provide a large amount of angiogenic cytokines highly vascularized porosity flexibility; | [ | |
| Induced microtissues | Preclinical | NA | NA | NA | In vivo | functional layering; single continuous urothelium | [ | |
| Cell sheet grafts | Oral epithelial cell and muscle cells | Preclinical | Canine | 2 cm | 12 weeks | In vivo | stratified urothelium intact muscle layer wide caliber | [ |
| Fibroblasts, ECs and UCs | Preclinical | NA | NA | NA | In vivo | promote the formation of blood vessel reduce necrosis; | [ | |
| Bidirectionally induced ADSCs | Preclinical | Rabbit | 2 cm | 6months | In vivo | stable multilayer epithelial cell layer; significant vascularization; Visible smooth muscle layer | [ | |
| Oral mucosal epithelial cells, oral fibroblasts and ADSCs | Preclinical | Canine | 2 cm | 3 months | In vivo | regenerated tissue similar to natural urethra | [ |
NA not available
Fig. 2Overview of key components in the study. A The scheme diagram of tissue-engineered bionic urethras using cell sheet technology. B Cell sheet formation and identification. Cell sheet formation after 21 days of continuous culture. The first line shows photographs of each of the types of cell sheets; the second line show H&E staining results of three cell sheets, which revealed that the cultured oral mucosal epithelial cell sheets were composed of 2–3 layers of cells (left, scale bar: 50 μm), the cultured oral fibroblast cell sheets were composed of 3–4 layers of cells (middle, scale bar: 100 μm), and the cultured myoblast induction of ADSCs sheets were composed of 6–7 layers of cells (right, scale bar: 100 μm); the third line shows the SEM images of the three cell sheets, scale bar: 50 μm. C Characterization of USPIO a TEM image; b the diameter distribution from TEM; c The XRD pattern of the synthesized USPIO; d The value of T2 relaxation rate of the synthesized USPIO as a function of Fe concentration from MRI of USPIO in tissue-engineered bionic urethra. D Macroscopic examination of retrieved urethra at 3 months after full-thickness urethral reconstruction. Similar to normal urethra, no ulcerations, strictures, and fistulas were observed in bionic urethra implants and buccal mucosa implants, but extensive contracture and scarring tissue at the graft site was found in SIS grafts. scale bar: 1.0 cm
Overview of scaffold grafts in urethral reconstruction
| Scaffold grafts | Biomaterials | Animals for modeling | Repaired length | Follow-up/study period | In vivo/in vitro | Results | References |
|---|---|---|---|---|---|---|---|
| Core-shell structure scaffolds | Collagen/P(LLA-CL) | rabbit | 2 cm | 3 months | In vivo | wide caliber; less collagen; more smooth muscle; thicker epithelium | [ |
| Collagen/P(LLA-CL) | dog | 2 cm | 12 weeks | In vivo | abundant ECM; better plasticity and strength; Inhibit fibrin deposition | [ | |
| Single-layer scaffolds | BAM | rabbit | 2 cm | 6months | In vivo | multiple layers of continuous urethral epithelium; upregulated the expression of myosin | [ |
| BAM | canine | 6 cm | 12months | In vivo | continuous muscle layers and epithelial layers; wide caliber | [ | |
| Porcine urethras | NA | NA | 14days | In vitro | Imitate the microstructure and composition of natural tissues | [ | |
| BC | Rabbit | 2 cm | 3months | In vivo | Improve cell biological activity; Low immunogenicity | [ | |
| BC/BAM | Rabbit | 1 cm | 3months | In vivo | Accelerate angiogenesis; Wide caliber; Multiple layers of continuous urethral epithelium | [ | |
| SF | Canine | 5 cm | 6months | In vivo | Complete epidermal layer and fibrolblast layer structure | [ | |
| hdCGTs | rabbit | 2 cm | 3months | In vivo | Wide caliber; Improve graft stability; Low immunogenicity | [ | |
| CCC | Minipig | 2 cm | 24 weeks | In vivo | Multiple layers of continuous urethral epithelium; Low immunogenicity; Outstanding stability and storability | [ | |
| cPUU | rabbit | 1.5 cm | 3 months | In vivo | High mechanical strength; Wide caliber; Reduced complication rate | [ | |
| Human amniotic | canine | 3 cm | 8 weeks | In vivo | Promote angiogenesis; Multiple layers of continuous urethral epithelium; Less scar tissue | [ | |
| AM | rabbit | 1 cm | 3months | In vivo | Simplify surgery procedure; Reduce postoperative complications; Good biocompatibility and low immunogenicity | [ | |
| AM | rabbit | 2 cm | 1months | In vivo | Low immunogenicity; High blood vessel density | [ | |
| Bilayer composite scaffolds | Epithelial-muscular | Canine | 1 cm | 3months | In vivo | Effectively mimick native structure of urethra | [ |
BSM- Autologous urethral tissue | Rabbit | 2 cm | 12 weeks | In vivo | Avoid cell expansion procedures; Excellent processability; Nonimmunogenicity | [ | |
| SF-SF | Rabbit | 2 cm | 3months | In vivo | High porosity; Help smooth muscle and epithelial tissue regeneration | [ | |
| SF-SF | Rabbit | 1 cm | 3months | In vivo | Neurovascularized urethral tissue; Wide caliber | [ | |
| BAMH/SF | Rabbit | 2.5 cm | 3months | In vivo | Promote vascularization; Promote regeneration of urothelium and smooth muscle; Wide caliber | [ | |
| BAMG/SF | rabbit | 1.5 cm | 3months | In vivo | Enhance cell adhesion and proliferation; Reduce collagen deposition; Promote vascularization | [ | |
| BC-SF | canine | 5 cm | 3months | In vivo | High porosity; Facilitate cell adhesion and proliferation; Promote angiogenesis | [ | |
| PLLA/PLGA/PCL-PLLA/PLGA/PLCL | Rabbit | 2 cm | 6months | In vivo | layered repair of urethra; wide caliber | [ | |
Collagen/ Elastin | NA | NA | NA | In vitro | Mimic natural structure; Excellent mechanical properties; Promote cell infiltration | [ | |
| Tri-layer composite scaffolds | PLA-PHBV-PLA | NA | NA | 28days | In vitro | None-immunogenicity; High mechanical strength | [ |
PLLA/ Gelatin | Rabbit | 2.2 cm | 3months | In vivo | Oriented SMC; Wide caliber; Promote angiogenesis | [ | |
| Collagen-PCL-collagen | NA | NA | 14days | In vitro | Facilitate cell adhesion and proliferation; High mechanical strength | [ | |
| PU-alt copolymer | Rabbit | 2.2 cm | 3months | In vivo | Promote the expression of α-SMA and AE1/AE3; Induce immune cell apoptosis; Simulate urethral structure | [ | |
| PU-alt copolymer | canine | 2.2 cm | 3months | In vivo | Promote vascularization; Mimic natural structure; Good mechanical properties | [ | |
| PCL/PLCL | NA | NA | NA | In vitro | High porosity; High mechanical strength | [ | |
| Other multilayer scaffolds | SIS | Rabbit | 1 cm | 9months | In vivo | Complete urothelium layers; No effective aggregation of smooth muscle cells | [ |
| SIS | NA | Average 2.7 cm | Average 23months | In vivo | Insufficient mechanical strength and degradation; Affect cell adhesion and proliferation | [ |
Fig. 3Overview of key components in the study. A The flowchart of study design. B The tensile strength of nanoyarn, conjugated scaffold and BAMG. C FTIR for different polymers in PLCL, control nanoyarn and drug (ICG-001) delivering nanoyarn. D Relative expression quantification of fibrosis related proteins [Collagen type I (Col I), Collagen type III (Col III)] were evaluated. *indicates significant difference (p < 0.05, comparing to control). E Sonourethrography and ultrasonic contrast examinations for the urethras repaired with ICG-001-delivering nanoyarn. a, c Sonourethrography examination results. b, d Ultrasonic contrast examination results
Fig. 4Design, processing and architecture of the bioinspired BC/BAM scaffold. A Schematic showing the preparation of BC/BAM scaffold. B Cell number of HUVECs cultured on BC, BAM and BC/BAM scaffolds measured by CCK-8 assay. C ELISA detection for levels of VEGF in BC, BAM and BC/BAM group during in vitro culture. Urethrography images of BC/BAM (D, E) group. The red arrows represent the urethrography site of the urethra. F Photographs for the shape adaptability of BC/BAM scaffold. G Photographs of the BC0.5/BAM0.5 scaffold under a compressing and releasing cycle
Fig. 5Overview of key components in the study. A Structural characterization of silk fibroin scaffold. Photomicrographs of gross scaffold morphology (scale bar: 1 cm) and SEM images of cross-sectional and top views of bilayer scaffold architecture (scale bars: 400 mm). B Eosinophil granulocytes (acute inflammation, denoted by arrows) present in de novo tissue supported by silk fibroin scaffolds. a Scale bars: 200 mm, b scale bar: 100 mm. C Histological evaluations (MTS analyses) of urethral tissue regeneration in control and implant groups following 3 m postop. Magnified de novo smooth muscle (SM) and epithelial (EP) tissue formation displayed in 3rd column. Scale bars: 200 mm. D Histomorphometric analysis of the extent of regenerated a-SMA + smooth muscle bundles (a), CK + epithelium (b), and CD31 + vessels (c) present in the original surgical sites of control and scaffold groups
Fig. 6Design, processing and architecture of the PCL/PLCL scaffold. A (a, b) The CT scanning images of the urethra; (d-f) The CT scanning images of the urethra filled with contrast reagent; (g) 2D slice (single layer) of the urethra design made using the WFIRM printing code program; where Red: UCs-laden hydrogel; Green: scaffold made of PCL/PLCL 50:50 blend; and Blue: SMCs-laden hydrogel. (h) The 3D rendering of the urethral design with porous scaffold and two hydrogel layers as seen using the WFIRM printing code program. B (a) PCL scaffold with columnar design; (b) PCL scaffold with spiral design; (c) PCL/PLCL (50:50) scaffold with columnar design; (d) PCL/PLCL (50:50) scaffold with spiral design; (e) native rabbit urethra. Scale bar: 2 mm (C) Stress testing of spiral and columnar scaffolds with PCL/PLCL blend (50:50). (D) UCs (labeled with green fluorescent dye) as seen in the hydrogel component of the bioprinted urethral construct after 1 day and 7 days of culture (a, c) and SMCs (labeled with red fluorescent dye) in the hydrogel component of the bioprinted urethral construct after 1 day of culture (b, d). Scale bar: 100 μm